What is Fastin and how is it used?
Fastin is a prescription medicine used to treat the symptoms of Obesity. Fastin may be used alone or with other medications.
Fastin belongs to a class of drugs called CNS Stimulants, Anorexiants; Stimulants; Sympathomimetic.
It is not known if Fastin is safe and effective in children younger than 16 years of age.
What are the possible side effects of Fastin?
Fastin may cause serious side effects including:
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- swelling of your ankle and leg swelling,
- bluish color of the lips or skin,
- chest pain or pressure,
- abdominal swelling, and
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Fastin include:
- fast heart rate (tachycardia),
- elevated blood pressure,
- dry mouth,
- dry mouth,
- unpleasant taste in your month,
- feeling uneasy,
- headache, and
- changes in sex drive
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Fastin. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Each phentermine hydrochloride capsule contains phentermine hydrochloride, 30 mg (equivalent to 24 mg Phentermine).
Phentermine Hydrochloride is a white crystalline powder, very soluble in water and alcohol. Chemically, the product is phenyl-tertiary-butylamine hydrochloride. Inactive Ingredients: F D & C Blue 1, Methylcellulose, Polyethylene Glycol, Starch, Titanium Dioxide, Sucrose and Invert Sugar. The branding ink used on the gelatin capsules contains: Ethyl Alcohol, F D & C Blue 1 Aluminum Lake, Isopropyl Alcohol, n-Butyl Alcohol, Propylene Glycol, Pharmaceutical Shellac (modified) or Refined Shellac (Food Grade).
1 pharmacies near 20147 have coupons for fastin (Brand Names:Fastin for 30MG)
Est. Regular Price
with free coupon
Phentermine hydrochloride is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use.
DOSAGE AND ADMINISTRATION
Administration of one capsule (30 mg) daily has been found to be adequate in depression of the appetite for twelve to fourteen hours.
Phentermine hydrochloride is not recommended for use in children under 12 years of age.
No information provided.
Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.
Tolerance to the anorectic effect usually develops within a few weeks. When this occurs, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.
Phentermine hydrochloride may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.
Drug Dependence: Phentermine hydrochloride is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been extensively abused, and the possibility of abuse of phentermine hydrochloride should be kept in mind when evaluating the desirability of including a drug as proof of a weight reduction program. Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia.
Usage in Pregnancy: Safe use in pregnancy has not been established. Use of phentermine hydrochloride by women who are or who may become pregnant, and those in the first trimester of pregnancy, requires that the potential benefit be weighed against the possible hazard to mother and infant.
Usage in Children: Phentermine hydrochloride is not recommended for use in children under 12 years of age.
Caution is to be exercised in prescribing phentermine hydrochloride for patients with even mild hypertension.
Phentermine hydrochloride may decrease the hypotensive effect of guanethidine.
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
Manifestations of acute overdosage with phentermine include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma.
Management of acute phentermine intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (REGITINE) has been suggested for possible acute, severe hypertension, if this complicates phentermine overdosage.
Patients with a history of drug abuse.
During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).
Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." It has not been established that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions, or metabolic effects may be involved, for example.
Adult obese subjects instructed in dietary management and treated with "anorectic" drugs, lose more weight on the average than those treated with placebo and diet, as determined in relatively short-term clinical trials.
The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an "anorectic" drug varies from trial to trial, and the increased weight loss appears to be related in proof to variables other than the drugs prescribed, such as the physician-investigator, the population treated, and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.
The natural history of obesity is measured in years, whereas the studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors